Helicobacter by Miernyk, KM et al.
Prevalence of Helicobacter pylori among Alaskans: Factors 
Associated with Infection and Comparison of Urea Breath Test 
and Anti-Helicobacter pylori IgG antibodies
KM Miernyk1, LR Bulkow1, BD Gold2, MG Bruce1, DH Hurlburt1, PM Griffin3, D Swerdlow3, 
K Cook4, T Hennessy1, and AJ Parkinson1
1Arctic Investigations Program, Division of Preparedness and Emerging Infections, National 
Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and 
Prevention; Anchorage, Alaska USA.
2Children’s Center for Digestive Healthcare, LLC; Atlanta, Georgia USA.
3Enteric Diseases Epidemiology Branch, Division of Foodborne, Waterborne, and Environmental 
Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease 
Control and Prevention; Atlanta, Georgia USA.
4Kiel Laboratories, Inc.; Flowery Branch, Georgia USA.
Abstract
Background: Helicobacter pylori is one of the most common human infections in the world and 
studies in Alaska Native people, as well as other Indigenous peoples, have shown a high 
prevalence of this gastric infection. This study was undertaken to determine the prevalence of H. 
pylori infection by urea breath test (UBT) and anti-H. pylori IgG among Alaskans living in four 
regions of the state and to identify factors associated with infection.
Methods: A convenience sample of persons > 6 months old living in five rural and one urban 
Alaskan community were recruited from 1996 to 1997. Participants were asked about factors 
possibly associated with infection. Sera were collected and tested for anti-H. pylori IgG 
antibodies; a UBT was administered to participants > 5 years old.
Results: We recruited 710 people of whom 571 (80%) were Alaska Native and 467 (66%) were 
from rural communities. Rural residents were more likely to be Alaska Native compared with 
urban residents (p<0.001). Of the 710 people, 699 (98%) had a serum sample analyzed and 634 
(97%) persons > 5 years old had a UBT performed. H. pylori prevalence was 69% by UBT and 
68% by anti-H. pylori IgG. Among those with a result for both tests, there was 94% concordance. 
Factors associated with H. pylori positivity were Alaska Native racial status, age ≥ 20 years, rural 
region of residence, living in a crowded home, and drinking water that was not piped or delivered.
Conclusions: H. pylori prevalence is high in Alaska, especially in Alaska Native persons and 
rural residents. Concordance between UBT and serology was also high in this group. Two 
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socioeconomic factors, crowding and drinking water that was not piped or delivered, were found 
to be associated with H. pylori positivity.
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Introduction
Helicobacter pylori is one of the most common human infections with over 50% of persons 
infected in some countries (1). Numerous studies from around the world have shown that the 
prevalence of H. pylori infection is related to age, gender, ethnicity, and a variety of 
socioeconomic indicators (2–6); moreover, intrafamilial clustering also occurs (7–10). H. 
pylori colonization of the stomach results in an inflammatory response, gastritis, that can 
persist for decades (11), and infected persons have a 10 to 20% lifetime risk of developing 
peptic ulcer disease and a 1 to 2% lifetime risk of developing gastric cancer, particularly in 
populations with specific host-genetic risk (12–14). Because of this, H. pylori is 
characterized as a group I carcinogen by the International Agency for Research on Cancer 
(World Health Organization) (15).
Gastric cancer incidence and mortality is decreasing in many parts of the world, but this is 
not true for Alaska Native people for whom gastric cancer is the third most common cause 
of cancer-related death (16–18). Additionally, the gastric cancer mortality rate among 
Alaska Native people is more than three times higher than among U.S. whites (11.3 vs. 3.2 
per 100,000 persons) (19). Past studies in Alaska have shown that H. pylori-infected persons 
have a higher risk of gastric cancer compared with non-infected persons and that 75% of 
Alaska Native people have H. pylori IgG antibodies (20, 21). This study was undertaken to 
determine the prevalence of H. pylori infection by both urea breath test (UBT) and anti-H. 
pylori IgG among Alaskans living in four regions of the state and to identify factors 
associated with infection.
Methods
Study Participants
Persons living in five rural Alaska Native communities and one urban city were invited to 
participate. The six communities were selected to represent four geographic regions (Figure 
1). Study approval was obtained from the regional health corporations and village 
leadership. The study was approved by Institutional Review Boards of the Centers for 
Disease Control and Prevention and the Alaska Area Indian Health Service.
Recruitment occurred during 1996 and 1997. A convenience sample of persons living in all 
six communities were recruited using public advertisements and personal contact with study 
staff. All residents >6 months old were eligible to enroll. Participants ≥18 years old provided 
written, informed consent whereas parents or legal guardians provided consent for 
participants <18 years old.
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Data collection
The head of a household provided information about the number of household members, 
size of the house, and drinking water source(s) for the home. We obtained age, sex, ethnicity, 
education level, and water use behaviors for individual household members. We also asked 
about clinical information and medication use that could be related to an H. pylori infection. 
A chart review was not done to confirm the self-reported clinical information nor did we 
confirm whether or not the clinical diagnoses (gastritis, ulcer, gastric cancer, H. pylori 
infection) were determined by esophagogastroduodenoscopy.
From each participant, we collected a whole blood specimen in a standard serum separator 
tube. We centrifuged the specimens in the field, decanted the serum, and transported them on 
ice packs to Anchorage where they were frozen at −30oC until analysis. After all sera were 
collected, they were shipped to the CDC’s Foodborne and Diarrheal Diseases Laboratory in 
Atlanta where they were tested for H. pylori IgG antibodies with an enzyme-linked 
immunosorbent assay (ELISA) used previously in this population (21–23). This assay has a 
sensitivity of 92% and a specificity of 98% compared with upper endoscopy. A value of ≥0.8 
was considered positive.
Each participant >5 years old underwent a urea breath test (UBT) for current H. pylori 
infection using the commercial Meretek UBT® (now called BreathTek UBT, Otsuka 
Pharmaceuticals) according to the manufacturer’s instructions. Discontinuation of 
medications was not a requirement for UBT testing. Breath samples were kept at room 
temperature and sent to the Meretek testing laboratory (Houston, TX) where they were 
assessed for 13CO2 by mass spectrophotometry. The amount of 13CO2 in each person’s 
baseline and 30-minute samples was compared and a ratio of >2.4 was considered positive.
Statistical analysis
Proportions were compared using a chi-squared or Fisher’s exact test as appropriate, and 
logistic regression was used to examine multiple factors simultaneously. All factors were 
examined in a univariate fashion to assess preliminary significance. In addition, multiple 
options for grouping categorical and ordinal variables were assessed. A backwards selection 
procedure was used beginning with a comprehensive model with all factors; the adjusted 
odds-ratios for all factors are reported. Logistic regression analyses were repeated treating 
household as a random effect with very similar results (not presented). Water use in a village 
was classified into two groups, “Piped and delivered water only” and “Other water sources”. 
The former included piped municipal water, well water, water delivered by municipal truck, 
and bottled water; the latter included water hauled from a municipal spigot and natural water 
sources such as that from rivers and lakes, or acquired from rain or melted snow and ice. 
Analyses were performed using Stata V10. P-values are two-sided and those less 0.05 are 
considered statistically significant.
Results
We recruited 710 people (age range, 2–92 years) of whom 382 (54%) were female and 571 
(80%) were Alaska Native (Table 1). Participants from rural regions A-C were more likely to 
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be Alaska Native than participants from urban region D (p<0.001; Figure 1). As compared 
with the 2000 census population for these six communities, study participants were more 
likely to be female and Alaska Native. This remains true when the rural and urban 
communities are analyzed separately. The most common clinical symptom related to a 
possible H. pylori infection was stomach pain, with 33% of participants reporting it. 
Diagnoses of gastritis, ulcer, gastric cancer, or a previous H. pylori infection were 
uncommon with 7%, 8%, 0.1%, and 1%, respectively, of persons reporting each (Table 1).
We analyzed UBT samples from 634 (97%) of 655 eligible persons >5 years old. Six 
persons had indeterminate results and were not included in the final analysis. Characteristics 
of the remaining 628 persons are in Table 2. We analyzed 699 serum samples for IgG 
antibodies to H. pylori (Table 2). H. pylori prevalence was similar by UBT and anti-H. pylori 
IgG (69% and 68%, respectively). For persons with a result for both tests, there was 94% 
concordance between the two results.
Univariate analysis showed that H. pylori positivity as detected by UBT or anti-H. pylori 
IgG was associated with Alaska Native race, rural region of residence, being part of a large 
family, living in a more crowded house, and, among persons ≥20 years old, having ≤12 years 
of education (Table 2). Gender was not associated with H. pylori positivity using either test. 
In multivariate analysis, factors associated with H. pylori positivity were Alaska Native 
racial status, age ≥20 years old, and rural region of residence. Household crowding remained 
associated with seropositivity but not a positive UBT.
In the three rural regions where drinking water sources could vary, active H. pylori infection 
as detected by UBT was associated with drinking water source (Table 3). Persons having 
access to municipal piped or delivered sources of water had a lower prevalence of infection. 
Moreover, among persons <20 years old, access to municipal piped or delivered water was 
also associated with a lower prevalence of anti-H. pylori IgG.
Discussion
Despite the high H. pylori seroprevalence (21) and high rates of gastric cancer in the Alaska 
Native people (19), few studies have been published investigating factors in this population 
that may be associated with infection. In this 1996–1997 study of H. pylori infection in four 
Alaska regions using UBT and serology, we found associations between H. pylori positivity 
and race, rural residence, and age ≥ 20 years old. Two socioeconomic factors, living in a 
crowded home and drinking water source, were also associated with infection. Prevalence 
was nearly 70% for both UBT and serology and concordance between the two tests was 
high, at 94%.
H. pylori prevalence varies around the world. Recent reviews by Peleteiro et al. and Eusesbi 
et al. reported prevalence ranging from 13% in Finland and the United Kingdom to 94% in 
Nigeria (3, 24). Data collected from the 1999–2000 United States National Health and 
Nutrition Examination Surveys show an all-ages U.S. seroprevalence of 27% (25). The 
prevalence in our study, particularly among Alaska Native people, is similar to the 
prevalence reported in developing countries rather than the general U.S. population (3, 5, 24, 
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26). It is also high when compared with the prevalence among Aboriginal adults living in 
Arctic communities. In a review of six relevant studies of H. pylori prevalence among 
Aboriginal populations of Canada, Greenland, and Russia, Goodman et al. identified only 
two populations with a prevalence higher than the Alaska Natives in our study (27). One was 
from Arctic Russia in 1990 (prevalence 77%) and the other from Northern Manitoba in 1996 
(prevalence 95%) (28, 29).
Similar to other populations, socioeconomic factors are likely the major reason for the high 
prevalence of H. pylori infection in Alaska (1, 30–35). Our finding that H. pylori infection is 
associated with living in a more crowded home is not surprising because crowding leads to 
close contact between household members and H. pylori transmission is mainly intrafamilial 
(1). Other studies have shown intrafamilial clustering of infections (7–10) and in a previous 
study conducted in Alaska, household family members’ infection status was associated with 
risk of becoming reinfected with H. pylori after successful eradication (36).
Water source has been identified as a possible risk factor for H. pylori infection in other 
epidemiologic studies (32, 37–40) and H. pylori organisms have been detected in a variety of 
water sources (40–43). We did not test water as part of this study; however, ingestion is not 
the only means of transmission potentially affected by water. Lee et al. showed that 
infrequent hand washing was associated with increased prevalence of H. pylori in Malaysia 
(44) suggesting that H. pylori infection could be related to inadequate hygiene practices. 
Previously, we have identified lack of in-home water service in Alaska to be a risk factor for 
reinfection with H. pylori (36) as well as for skin and respiratory infections (45–47). It is 
possible that the availability of clean water was a surrogate for the availability of water in 
general and that lack of water for hygiene contributed to transmission in the rural 
communities. More work is needed to better understand improvement in water source as a 
potential approach to preventing infection.
In this population H. pylori is typically acquired in childhood, thus it is not surprising we 
found increasing prevalence until adulthood. In persons >20 years old, prevalence appeared 
stable at about 70%. In contrast, other groups have found increasing prevalence past 20 years 
of age (6, 34, 35, 48–52). It is thought that the increase in prevalence in older age groups is 
due to a birth cohort effect in which childhood acquisition rates have decreased over time 
presumably due to improved sanitary, hygiene, and socioeconomic factors in subsequent 
generations of children. However, overall seroprevalence rates do not appear to be 
decreasing in rural Alaska. Prevalence in this 1996–1997 study was similar to that found in a 
serosurvey from 1980–1986 (21). This is an important observation because gastric cancer 
incidence remains high among Alaska Native people (16). Peleteiro et al. presented an 
analysis of gastric cancer incidence as it relates to H. pylori prevalence around the world, 
concluding that prevalence of infection was at least two-fold higher in countries with high 
gastric cancer incidence (24). High H. pylori prevalence in Alaska is likely at least partly 
responsible for the continued high incidence of gastric cancer among the Alaska Native 
people and, as there is no evidence of improvement, it is becoming increasingly important to 
develop strategies to address this disparity.
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This is one of the few studies that tested for H. pylori infection in the same people using 
both UBT and serology; the 94% concordance is informative. Using serology to diagnose an 
H. pylori infection is not recommended in populations where infection is common (53). This 
is because antibodies circulate long after eradication, so many people who are no longer 
infected may have a positive test result, resulting in a low test specificity (54). However, a 
study by Bruden et al. showed that false positive serology results were associated with 
previous H. pylori treatment (55). In our study group, a previous H. pylori diagnosis was 
uncommon at study entry, so it is unlikely many participants had formerly been treated for 
the infection. Therefore, data from our study suggests that UBT and serology results are 
comparable when persons have not been previously treated for infection. We can have 
confidence comparing results across studies of untreated populations where prevalence of 
infection was determined using different methods.
This study has four important limitations. A cross-sectional survey that includes primarily 
adults is not a suitable method for understanding factors associated with an infection usually 
acquired during childhood, because factors may have changed over time. However, it is 
likely that many of the factors studied, related to living in rural, primarily Alaska Native 
communities, did not change for many persons between the time they acquired an H. pylori 
infection and the time of the study. The convenience sampling methodology we used, 
particularly in the urban region, may have resulted in a non-representative sample. 
Therefore, generalizations to the entire population should be made with caution. The water 
source used and reported at the time of the study may have been different from the water 
source used when the organism was acquired. Finally, the samples were collected and tested 
over 20 years ago and H. pylori prevalence may have changed during that time. However, 
numerous studies published since these data were collected show that H. pylori infection and 
gastric cancer continue to negatively affect the Alaska Native people (16, 36, 53, 56, 57). 
Thus, it is important these older data be published as a prevalence baseline as we continue to 
address this health disparity.
In conclusion, H. pylori prevalence is high in Alaska, especially in Alaska Native people. 
Concordance between UBT and serology was high which gives increased validity to the 
results and confidence in interpreting data between studies of untreated persons that use 
different testing methods. Socioeconomic factors associated with infection in Alaskans are 
living in a crowded home and drinking water from a less protected source. The prevalence in 
this study conducted in the late 1990s was similar to a seroprevalence study from the 1980s. 
This, combined with the stable prevalence in persons ≥ 20 years old in this study, indicate 
more recent birth cohorts may not be at decreased risk of H. pylori infection as seen in other 
populations around the world. This has health implications for addressing the high incidence 
of gastric cancer in the Alaska Native people. Because the socioeconomic conditions in rural 
Alaska are similar now as compared with 20 years ago, an updated prevalence study in a 
similar cohort could be considered to investigate whether or not prevalence continues to be 
stable.
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Figure 1. 
Map of Alaska with study regions identified; Alaska 1996–1997.
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